DNMT/G9a Complex Inhibition Uncovers Epigenetic Vulnerabilities and Induces IFN-Response in Acute Myeloid Leukemia
Schoenefeld, A.; Zanetti, C.; Schmitt, E. C.; Woods, K.; Westerback, A.; Mitsch, S. M.; Ruehle, F.; Kelekeci, S.; Fol, L.; Shah, V.; Sanchez-Saez, M.; Thevissen, S.; Schaeffer, A.; Schmits, U. R.; Sasca, D.; Kindler, T.; Woelfel, C.; Feuerstein-Akgoz, C.; Gerhaeuser, C.; Lutsik, P.; Riviere, J.; Hecker, J. S.; Goetze, K. S.; Platzbecker, U.; Echchannaoui, H.; Theobald, M.; Plass, C.; Padeken, J.; Medyouf, H.; Guezguez, B.
Show abstract
Epigenetic dysregulation is a hallmark of Acute Myeloid Leukemia (AML), with mutations in DNA Methyltransferases (e.g., DNMT3A) being frequent and promising therapeutic targets. DNMTs form complexes with Histone Methyltransferases (HMTs), driving gene silencing loop via chromatin methylation crosstalk. However, potential connections between this DNMTs/HMTs cooperative activity and oncogenic requirements across the AML mutational spectrum remain poorly understood. Here, we demonstrate that AMLs carrying DNMT3A and Nucleophosmin (NPM1) mutations exhibit a specific epigenetic vulnerability toward a complex formed by DNMTs and G9a, a specific histone H3 Lysine 9 Methyltransferase (H3K9-HMT). Dual inhibition of DNMT/G9a restores differentiation, reduces tumor growth, and spares healthy progenitors compared to standard hypomethylating agents. Mechanistically, DNMT/G9a regulates NPM1 stability, inhibits HOXA9/MEIS1 activity, and triggers interferons (IFN) response via viral mimicry pathways by modulating hypermethylated retrotransposons. Collectively, our data unravel specific epigenetic vulnerabilities within the complex AML mutational landscape and provide a compelling rationale for the design of personalized epigenetic therapies with enhanced efficacy and safer clinical outcomes.
Matching journals
The top 7 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- AML/T cell interactomics uncover correlates of patient outcomes and the key role of ICAM1 in T cell killing of AML 98%
- Resistance to decitabine and 5-azacytidine emerges from adaptive responses of the pyrimidine metabolism network 97%
- Mapping AML heterogeneity – multi-cohort transcriptomic analysis identifies novel clusters and divergent ex-vivo drug responses 97%
Similar papers in this journal
Similar papers in this journal
- BRG1/BRM inhibitor targets AML stem cells and exerts superior preclinical efficacy combined with BET or Menin inhibitor 97%
- A JAK/STAT-Mediated Inflammatory Signaling Cascade Drives Oncogenesis In AF10-Rearranged AML 96%
- Myeloid lncRNA LOUP Mediates Opposing Regulatory Effects of RUNX1 and RUNX1-ETO in t(8;21) AML 96%
Similar papers in this journal
- Extracellular ATP and CD39 activate cAMP-mediated mitochondrial stress response to promote cytarabine resistance in acute myeloid leukemia 97%
- Leukemia cell of origin influences apoptotic priming and sensitivity to LSD1 inhibition 97%
- Reprogramming of serine metabolism is an actionable vulnerability in FLT3-ITD driven acute myeloid leukaemia 96%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.